{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:32:12Z","timestamp":1778023932506,"version":"3.51.4"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202850"],"award-info":[{"award-number":["82202850"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013153","name":"Shantou Science and Technology Project","doi-asserted-by":"publisher","award":["230509116495542"],"award-info":[{"award-number":["230509116495542"]}],"id":[{"id":"10.13039\/501100013153","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012797"],"award-info":[{"award-number":["2025A1515012797"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012473"],"award-info":[{"award-number":["2025A1515012473"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.phrs.2025.107978","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:57:03Z","timestamp":1759993023000},"page":"107978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PPM1G promotes chemoresistance in triple negative breast cancer by enhancing YAP signaling"],"prefix":"10.1016","volume":"221","author":[{"given":"Weiling","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XuWei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangfu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunpeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenchong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2025.107978_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.phrs.2025.107978_bib2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107978_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast cancer research BCR"},{"issue":"15 Pt 1","key":"10.1016\/j.phrs.2025.107978_bib6","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"12","key":"10.1016\/j.phrs.2025.107978_bib7","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/annonc\/mdp492","article-title":"Triple-negative breast cancer--current status and future directions","volume":"20","author":"Gluz","year":"2009","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107978_bib8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.22.02572","article-title":"Response to neoadjuvant therapy and Long-Term survival in patients with Triple-Negative breast cancer","volume":"41","author":"Liedtke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107978_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pharmthera.2016.02.008","article-title":"Cancer stem cells and chemoresistance: the smartest survives the raid","volume":"160","author":"Zhao","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"19","key":"10.1016\/j.phrs.2025.107978_bib10","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.7150\/thno.41648","article-title":"Stem cell programs in cancer initiation, progression, and therapy resistance","volume":"10","author":"Huang","year":"2020","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.phrs.2025.107978_bib11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.107978_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcancer.2021.06.015","article-title":"Cancer stem cells in TNBC","volume":"82","author":"Hua","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107978_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107978_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","article-title":"Stem cell fate in cancer growth, progression and therapy resistance","volume":"18","author":"Lytle","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.107978_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ctrv.2018.07.004","article-title":"Cancer stem cell in breast cancer therapeutic resistance","volume":"69","author":"Bai","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2025.107978_bib17","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-09-2846","article-title":"Targeting Hedgehog--a cancer stem cell pathway","volume":"16","author":"Merchant","year":"2010","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"12","key":"10.1016\/j.phrs.2025.107978_bib18","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-09-2823","article-title":"Targeting notch to target cancer stem cells","volume":"16","author":"Pannuti","year":"2010","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"4","key":"10.1016\/j.phrs.2025.107978_bib19","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","article-title":"The biology of YAP\/TAZ: hippo signaling and beyond","volume":"94","author":"Piccolo","year":"2014","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2025.107978_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13238-012-2919-3","article-title":"The hippo pathway regulates stem cell proliferation, self-renewal, and differentiation","volume":"3","author":"Liu","year":"2012","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.107978_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","article-title":"The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells","volume":"147","author":"Cordenonsi","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gad.274027.115","article-title":"Mechanisms of hippo pathway regulation","volume":"30","author":"Meng","year":"2016","journal-title":"Genes Dev."},{"issue":"12","key":"10.1016\/j.phrs.2025.107978_bib23","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1002\/ijc.29293","article-title":"The hippo pathway in chemotherapeutic drug resistance","volume":"137","author":"Zhao","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2025.107978_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cells13070564","article-title":"Hippo signaling at the hallmarks of cancer and drug resistance","volume":"13","author":"Kumar","year":"2024","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.phrs.2025.107978_bib25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.semcdb.2012.05.004","article-title":"The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian hippo pathway","volume":"23","author":"Hong","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107978_bib26","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","article-title":"Elucidation of a universal size-control mechanism in drosophila and mammals","volume":"130","author":"Dong","year":"2007","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.1843810","article-title":"A coordinated phosphorylation by lats and CK1 regulates YAP stability through SCF(beta-TRCP)","volume":"24","author":"Zhao","year":"2010","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.phrs.2025.107978_bib28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ncb2303","article-title":"The hippo pathway in organ size control, tissue regeneration and stem cell self-renewal","volume":"13","author":"Zhao","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"21","key":"10.1016\/j.phrs.2025.107978_bib29","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1101\/gad.1602907","article-title":"Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control","volume":"21","author":"Zhao","year":"2007","journal-title":"Genes Dev."},{"issue":"16","key":"10.1016\/j.phrs.2025.107978_bib30","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/0008-5472.CAN-13-2712","article-title":"YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway","volume":"74","author":"Zhao","year":"2014","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.phrs.2025.107978_bib31","first-page":"2207","article-title":"Regulation of p27(Kip1) phosphorylation and G1 cell cycle progression by protein phosphatase PPM1G","volume":"6","author":"Sun","year":"2016","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2025.107978_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2012.01.021","article-title":"ATM-dependent downregulation of USP7\/HAUSP by PPM1G activates p53 response to DNA damage","volume":"45","author":"Khoronenkova","year":"2012","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1101\/gad.13.1.87","article-title":"The type 2C Ser\/Thr phosphatase PP2Cgamma is a pre-mRNA splicing factor","volume":"13","author":"Murray","year":"1999","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.phrs.2025.107978_bib34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1083\/jcb.200608001","article-title":"A novel histone exchange factor, protein phosphatase 2Cgamma, mediates the exchange and dephosphorylation of H2A-H2B","volume":"175","author":"Kimura","year":"2006","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107978_bib35","article-title":"High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma","author":"Xiong","year":"2021","journal-title":"Cancer Biomarkers Section A Disease markers"},{"issue":"8","key":"10.1016\/j.phrs.2025.107978_bib36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41419-021-04013-y","article-title":"PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3","volume":"12","author":"Chen","year":"2021","journal-title":"Cell death Dis."},{"issue":"9","key":"10.1016\/j.phrs.2025.107978_bib37","doi-asserted-by":"crossref","first-page":"12929","DOI":"10.18632\/aging.202964","article-title":"Prognostic and immunological potential of PPM1G in hepatocellular carcinoma","volume":"13","author":"Lin","year":"2021","journal-title":"Aging"},{"issue":"2","key":"10.1016\/j.phrs.2025.107978_bib38","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2023.13043","article-title":"Prognostic and immunological potential of PPM1G in lung adenocarcinoma","volume":"28","author":"Yin","year":"2023","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/carcin\/bgac090","article-title":"PPM1G promotes the progression of lung adenocarcinoma by inhibiting p38 activation via dephosphorylation of MEK6","volume":"44","author":"Chen","year":"2023","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.phrs.2025.107978_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216516","article-title":"SHC4 orchestrates \u03b2-catenin pathway-mediated metastasis in triple-negative breast cancer by promoting src kinase autophosphorylation","volume":"582","author":"Zhong","year":"2024","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.phrs.2025.107978_bib41","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-14-2191","article-title":"The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer","volume":"21","author":"Song","year":"2015","journal-title":"Clinical Cancer Res. Official J. American Association Cancer Res."},{"key":"10.1016\/j.phrs.2025.107978_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.phrs.2025.107978_bib43","article-title":"Taxanes in cancer treatment: activity, chemoresistance and its overcoming","volume":"54","author":"Mosca","year":"2021","journal-title":"Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother."},{"issue":"6","key":"10.1016\/j.phrs.2025.107978_bib44","doi-asserted-by":"crossref","first-page":"vi40","DOI":"10.1093\/annonc\/mds194","article-title":"Adjuvant treatments for triple-negative breast cancers","volume":"23","author":"Joensuu","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.phrs.2025.107978_bib45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semcancer.2019.07.022","article-title":"ME LL. Insights into new mechanisms and models of cancer stem cell multidrug resistance","volume":"60","author":"Garcia-Mayea","year":"2020","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-1130-z","article-title":"Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the hippo pathway and increasing the stemness","volume":"19","author":"Mu\u00f1oz-Galv\u00e1n","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/path.4995","article-title":"Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP\/TAZ activity","volume":"244","author":"Liu","year":"2018","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107978_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.340","article-title":"YAP\/TAZ: molecular pathway and disease therapy","volume":"4","author":"Wei","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.phrs.2025.107978_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.658481","article-title":"Hippo-Independent regulation of Yki\/Yap\/Taz: a Non-canonical view","volume":"9","author":"Cho","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib50","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1038\/s41467-018-07022-2","article-title":"Reciprocal inhibition of YAP\/TAZ and NF-\u03baB regulates osteoarthritic cartilage degradation","volume":"9","author":"Deng","year":"2018","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.phrs.2025.107978_bib51","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1158\/0008-5472.CAN-19-1339","article-title":"MK5 regulates YAP stability and is a molecular target in YAP-Driven cancers","volume":"79","author":"Seo","year":"2019","journal-title":"Cancer Res"},{"issue":"1-2","key":"10.1016\/j.phrs.2025.107978_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1101\/gad.333146.119","article-title":"CDK7 regulates organ size and tumor growth by safeguarding the hippo pathway effector Yki\/Yap\/Taz in the nucleus","volume":"34","author":"Cho","year":"2020","journal-title":"Genes Dev."},{"issue":"17","key":"10.1016\/j.phrs.2025.107978_bib53","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/CM9.0000000000001653","article-title":"Nuclear Dbf2-related kinase 1 functions as tumor suppressor in glioblastoma by phosphorylation of Yes-associated protein","volume":"134","author":"Chen","year":"2021","journal-title":"Chin. Med. J."},{"issue":"10","key":"10.1016\/j.phrs.2025.107978_bib54","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1074\/jbc.RA119.010783","article-title":"Furry protein suppresses nuclear localization of yes-associated protein (YAP) by activating NDR kinase and binding to YAP","volume":"295","author":"Irie","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2025.107978_bib55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cub.2014.11.054","article-title":"NDR functions as a physiological YAP1 kinase in the intestinal epithelium","volume":"25","author":"Zhang","year":"2015","journal-title":"Curr. Biol. CB"},{"issue":"8","key":"10.1016\/j.phrs.2025.107978_bib56","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.cellsig.2014.04.011","article-title":"Constitutively active NDR1-PIF kinase functions independent of MST1 and hMOB1 signalling","volume":"26","author":"Cook","year":"2014","journal-title":"Cell. Signal."},{"issue":"7","key":"10.1016\/j.phrs.2025.107978_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/biom14070749","article-title":"TFTF: an R-Based integrative tool for decoding human transcription Factor-Target interactions","volume":"14","author":"Wang","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13058-023-01675-8","article-title":"Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer","volume":"25","author":"Katzenellenbogen","year":"2023","journal-title":"Breast cancer research BCR"},{"issue":"22","key":"10.1016\/j.phrs.2025.107978_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16223823","article-title":"Therapeutic landscape of FOXM1 in Triple-Negative breast cancer and aggressive solid cancers","volume":"16","author":"Dilmac","year":"2024","journal-title":"Cancers"},{"issue":"Pt 3","key":"10.1016\/j.phrs.2025.107978_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2022.07.009","article-title":"Dysregulated FOXM1 signaling in the regulation of cancer stem cells","volume":"86","author":"Sher","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.phrs.2025.107978_bib61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2014.07.008","article-title":"FOXM1: a key oncofoetal transcription factor in health and disease","volume":"29","author":"Bella","year":"2014","journal-title":"Semin Cancer Biol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107978_bib62","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107978_bib63","unstructured":"!!! INVALID CITATION !!! (5, 59)."},{"key":"10.1016\/j.phrs.2025.107978_bib64","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother."},{"issue":"17","key":"10.1016\/j.phrs.2025.107978_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179644","article-title":"New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer","volume":"22","author":"An","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107978_bib66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2018.07.007","article-title":"Breast cancer stem cells: features, key drivers and treatment options","volume":"53","author":"Dittmer","year":"2018","journal-title":"Semin Cancer Biol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107978_bib67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/10409230701693342","article-title":"Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling","volume":"42","author":"Lammers","year":"2007","journal-title":"Crit. Rev. Biochem Mol. Biol."},{"key":"10.1016\/j.phrs.2025.107978_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107622","article-title":"Metal-dependent Ser\/Thr protein phosphatase PPM family: evolution, structures, diseases and inhibitors","volume":"215","author":"Kamada","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"22","key":"10.1016\/j.phrs.2025.107978_bib69","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1128\/MCB.00226-15","article-title":"PPM1G binds 7SK RNA and Hexim1 to block P-TEFb assembly into the 7SK snRNP and sustain transcription elongation","volume":"35","author":"Gudipaty","year":"2015","journal-title":"Mol. Cell. Biol."},{"issue":"44","key":"10.1016\/j.phrs.2025.107978_bib70","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1038\/onc.2016.115","article-title":"Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase","volume":"35","author":"Xu","year":"2016","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.phrs.2025.107978_bib71","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nsmb1257","article-title":"Alternative splicing regulation by interaction of phosphatase PP2Cgamma with nucleic acid-binding protein YB-1","volume":"14","author":"Allemand","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"20","key":"10.1016\/j.phrs.2025.107978_bib72","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cub.2009.09.020","article-title":"The MST1 and hMOB1 tumor suppressors control human centrosome duplication by regulating NDR kinase phosphorylation","volume":"19","author":"Hergovich","year":"2009","journal-title":"Curr. Biol. CB"},{"key":"10.1016\/j.phrs.2025.107978_bib73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.critrevonc.2015.12.004","article-title":"Hippo pathway and breast cancer stem cells","volume":"99","author":"Maugeri-Sacc\u00e0","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107978_bib74","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/0008-5472.CAN-17-2726","article-title":"Oncogenic Kinase-Induced PKM2 tyrosine 105 phosphorylation converts nononcogenic PKM2 to a tumor promoter and induces cancer Stem-like cells","volume":"78","author":"Zhou","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.phrs.2025.107978_bib75","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ signaling and resistance to cancer therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2025.107978_bib76","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13046-016-0338-7","article-title":"Topographic expression of the hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy","volume":"35","author":"Vici","year":"2016","journal-title":"J. Experimental .linical Cancer Res. CR"},{"issue":"8","key":"10.1016\/j.phrs.2025.107978_bib77","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","article-title":"YAP\/TAZ upstream signals and downstream responses","volume":"20","author":"Totaro","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107978_bib78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The hippo pathway: biology and pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2025.107978_bib79","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.semcancer.2017.04.010","article-title":"The NDR\/LATS protein kinases in immunology and cancer biology","volume":"48","author":"Sharif","year":"2018","journal-title":"Semin Cancer Biol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107978_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/genes7050021","article-title":"The roles of NDR protein kinases in hippo signalling","volume":"7","author":"Hergovich","year":"2016","journal-title":"Genes"},{"issue":"12","key":"10.1016\/j.phrs.2025.107978_bib81","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.phrs.2025.107978_bib82","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3892\/ol.2021.12964","article-title":"Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein survivin in a light-independent manner","volume":"22","author":"Hasegawa","year":"2021","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.phrs.2025.107978_bib83","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/cas.13138","article-title":"Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex","volume":"108","author":"Wei","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phrs.2025.107978_bib84","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.freeradbiomed.2024.01.003","article-title":"Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells","volume":"212","author":"Zhou","year":"2024","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.phrs.2025.107978_bib85","first-page":"694","article-title":"Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models","volume":"24","author":"Barrette","year":"2022","journal-title":"NeuroOncology"},{"issue":"22","key":"10.1016\/j.phrs.2025.107978_bib86","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1091\/mbc.E15-07-0456","article-title":"Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors","volume":"26","author":"Lin","year":"2015","journal-title":"Mol. Biol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107978_bib87","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2016.04.089","article-title":"Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance","volume":"474","author":"Lee","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:49:55Z","timestamp":1773154195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":87,"alternative-id":["S1043661825004037"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107978","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPM1G promotes chemoresistance in triple negative breast cancer by enhancing YAP signaling","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107978"}}